

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1-4. (Canceled).
5. (Currently Amended) ~~The compound of claim 4, which is~~ (2R,3S,4R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.
6. (Canceled).
7. (Currently Amended) ~~The compound of claim 6, wherein said~~ A compound ~~[[is]] selected from the group consisting of (2R,3R,4S,5R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrothiophene-3,4-diol, (2R,3R,4S,5R)-2-(2-chloro-6-methylaminopurin-9-yl)-5-hydroxymethyl-tetrahydrothiophene-3,4-diol, (2R,3R,4S,5R)-2-(2-chloro-6-methylaminopurin-9-yl)-5-hydroxymethyltetrahydrothiophene-3,4-diol, (2S,3S,4R,5R)-5-(6-amino-2-chloro-purin-9-yl)-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide, (2S,3S,4R,5R)-5-(2-chloro-6-methylaminopurin-9-yl)-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide, and (2S,3S,4R,5R)-5-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.~~
8. (Canceled).
9. (Currently Amended) ~~The compound of claim 8~~ claim 7, which is (2S,3R,4S,5R)-2-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrothiophene-3,4-diol.
- 10-20. (Canceled).
21. (Previously Presented) A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.
22. (Canceled).
23. (Previously Presented) A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

24. (Canceled).

25. (Previously Presented) A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.

26-28. (Canceled).

29. (Currently Amended) A method of antagonizing an A₃ adenosine receptor in an animal in need thereof ~~treating breast cancer~~ comprising administering to the animal an effective amount of a compound of claim 5.

30. (Canceled).

31. (Currently Amended) A method of ~~treating breast cancer~~ agonizing an A₃ adenosine receptor in an animal in need thereof comprising administering to the animal an effective amount of a compound of claim 7.

32-42. (Canceled).

43. (Currently Amended) The compound of claim 7, which is (2S,3S,4R,5R)-5-(6-amino-2-chloro-purin-9-yl)-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.

44. (Previously Presented) A pharmaceutical composition comprising the compound of claim 43 and a pharmaceutically acceptable carrier.

45. (Currently Amended) A method of ~~treating breast cancer~~ agonizing an A₃ adenosine receptor in an animal in need thereof comprising administering to the animal an effective amount of ~~[[a]]~~ the compound of claim 44 claim 43.

46-48. (Canceled).

49. (Currently Amended) The compound of ~~claim 6~~ claim 7, which is (2S,3S,4R,5R)-5-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.

50. (Previously Presented) A pharmaceutical composition comprising a compound of claim 49 and a pharmaceutically acceptable carrier.

51. (Previously Presented) A method of treating breast cancer in an animal comprising administering to the animal an effective amount of the compound of claim 49.

52. (New) (2R,3R,4S,5R)-2-(2-chloro-6-aminopurin-9-yl)-5-hydroxymethyltetrahydrothiophene-3,4-diol.

53. (New) A pharmaceutical composition comprising the compound of claim 52 and a pharmaceutically acceptable carrier.

54. (New) A method of antagonizing an A₃ adenosine receptor in an animal in need thereof comprising administering to the animal an effective amount of the compound of claim 52.

55. (New) The compound of claim 7, which is (2S,3S,4R,5R)-5-[2-chloro-6-methylaminopurin-9-yl]-3,4-dihydroxytetrahydrothiophene-2-carboxylic acid methyl amide.

56. (New) A pharmaceutical composition comprising the compound of claim 55 and a pharmaceutically acceptable carrier.

57. (New) A method of agonizing an A₃ adenosine receptor in an animal in need thereof comprising administering to the animal an effective amount of the compound of claim 55.